A new survey study suggests that psychedelic experiences evoke a distinctive sense of familiarity, even when surroundings feel strange or unfamiliar, a phenomenon researchers are calling psychedelic-evoked familiarity. The findings, published in the Journal of Psychoactive Drugs, draw on responses from a large international sample and point to a memory experience that may be clinically relevant, independent of ordinary personal memories or déjà vu.
Memory science distinguishes recollection from familiarity. Recollection relies on the hippocampus and involves retrieving specifics about when and where an event occurred, while familiarity is thought to arise from surrounding cortical regions and provides a general sense of having encountered something before without details.
Classic psychedelics such as psilocybin, LSD and DMT are known to stimulate serotonin 2A receptors. They are typically associated with vivid imagery and ego dissolution, yet users also describe a powerful sense of returning to something deeply familiar, sometimes on the very first trip.
The study’s lead author, David Wyndham Lawrence, an associate professor in the Temerty Faculty of Medicine at the University of Toronto, described the emergence of the paradox: “The question came up while we were coding nearly 3,800 DMT trip reports for an earlier study. … What struck me most was what sometimes came next.” He added that participants often described coming home, or knowing the beings they encountered, prompting the central question: how could something so far removed from ordinary experience feel so deeply familiar?
Psychoactive substances can pull recollection and familiarity in opposite directions as memories form. In earlier laboratory work co-authored by Manoj K. Doss of the University of Texas at Austin Dell Medical School, psilocybin or the synthetic psychedelic 2C-B reduced accuracy in recalling neutral or positive images while increasing false feelings of familiarity for new, emotionally charged pictures.
To understand how psychedelic familiarity compares with everyday states, Lawrence collaborated with Doss and Akira Robert O’Connor of the University of St Andrews on a comparative survey. Between November 2024 and February 2025, researchers recruited English-speaking adults via email and social media. Of 1,420 who opened the survey, 1,050 completed data for at least one condition—psychedelic trip, familiar everyday memory, or typical déjà vu. Respondents were predominantly male and white, with most living in the United States or Canada. The dataset is available from the authors on request.
In the psychedelic section, 868 participants completed the component, 800 of whom had prior psychedelic use. They reported their use of classic psychedelics—psilocybin, LSD, DMT, ayahuasca and mescaline—and related psychoactive compounds such as 5-MeO-DMT, salvinorin A, ketamine and MDMA.
Those who felt familiarity on a psychedelic trip identified the strongest single episode, including the drug, dose, setting, perceived authenticity and any lasting effects. Separately, 679 participants completed the autobiographical section rating a familiar everyday place or event, and 605 completed the déjà vu section, with 575 who had experienced déjà vu rating a typical episode.
For each experience, participants completed the 19‑item Sense of Familiarity Questionnaire, scored from 0 to 5, measuring comfort, nostalgia, belonging, and remembering, as well as extraordinary aspects such as encounters with familiar entities or journeys to an eternal realm. They also rated emotional intensity, comfort, novelty, strangeness and anxiety on a 1–7 scale.
Among those with a history of psychedelic use, 91.5% reported familiarity during at least one trip, including 41 individuals who experienced it on their very first psychedelic occasion. Familiarity was reported most often by users of DMT (75.8%) and psilocybin (63.0%), with roughly half of LSD, ayahuasca and 5‑MeO‑DMT users also reporting the sensation, and lower percentages for MDMA, mescaline, salvinorin A and ketamine.
When identifying the strongest single substance for familiarity, DMT was named by 34.7% of respondents, with psilocybin close behind at 31.3%. Most of these peak experiences occurred at home and during medium to large self-reported doses.
Timing data show that 95.5% of familiarity arose during the trip itself rather than upon later reflection, and 75.9% of those who specified a stage located it at the trip’s peak. Across all experiences, familiarity was most often linked to the subjective conscious state or emotions rather than physical objects.
In head-to-head comparisons, 84.9% of those who had both psychedelic and non‑drug familiarity rated their psychedelic experiences as more profound than personal autobiographical memories, and 82.5% judged them more profound than everyday déjà vu. Across all 19 questionnaire items, psychedelic experiences scored higher than both autobiographical memories and déjà vu, with the widest gap on transcendent items such as visiting an infinite realm or a home for consciousness.
On warmth-related measures, psychedelic trips carried a higher probability of feeling like home, at 51.8% versus 27.9% for personal memories; déjà vu scored 4.1% for feeling like home. Emotional ratings showed psychedelic familiarity as both highly comfortable and markedly novel and strange, with a median comfort score of 7, compared with 6 for autobiographical memories and 4 for déjà vu. Anxiety levels did not differ significantly across conditions.
Lawrence said the pattern was striking: “From the individual reports, we already had a sense of what psychedelic familiarity could feel like. What surprised me was how clearly it stood out when we looked at the survey responses together.” He added: “Compared with déjà vu and meaningful personal memories, people rated their psychedelic experiences as more familiar and more novel, as well as more emotionally intense and more comforting.”
The authors propose that psychedelics may decouple the brain’s recognition system from actual memory retrieval. They also suggest that within a single trip, early impressions can become intensely familiar later in the session and be mistaken for older memories. One possible mechanism involves the distribution of serotonin 2A receptors, which excite outer cortical regions involved in familiarity while activating inhibitory cells in deep memory structures like the hippocampus. The mere exposure effect may also underpin a sense of safety or grounding during therapy, aiding post‑session integration.
The researchers stress caution in interpretation. Co‑author Doss serves as an advisor to VCENNA and receives support from the Heffter Research Institute, the Center for MINDS, and several foundations, highlighting potential areas for future scrutiny. They also warn against treating reports of visiting realms beyond birth and death as evidence of actual journeys, noting that their data describe subjective experiences rather than metaphysical truths.
interview comments underscored the study’s limits. Because participants were recruited via social media and online psychedelic communities, the sample skews toward experienced male users, and the high prevalence of vivid familiarity experiences may not reflect the broader population of psychedelic users. Doses were self‑estimated, and subgroups for MDMA and 5‑MeO‑DMT were small, emphasising the need for controlled trials with standardised dosing in real-time settings.
Lawrence concluded: “Psychedelics give us a unique way to separate the feeling of familiarity from actual memory (recollection), which could provide an avenue to advance broader memory research and our understanding of how the brain generates that feeling in everyday life.” He added that familiarity might contribute to the positive and meaningful nature of these experiences and, if borne out in therapy, could be a feature worth understanding and cautious use in clinical settings.
The study, “Characterizing Psychedelic-Evoked Familiarity: A Comparative Study with Autobiographical and Déjà Vu Experiences,” was authored by David Wyndham Lawrence, Manoj K. Doss and Akira Robert O’Connor.
